Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   756 Trials   22406 News 


«12...313314315316317318319320321322323...401402»
  • ||||||||||  Biomarker, Journal:  Circulating Biomarkers of Accelerated Sarcopenia in Respiratory Diseases. (Pubmed Central) -  Oct 8, 2020   
    We found a modest-to-significant increase in the plasma markers of inflammation, oxidative stress and muscle damage, which had varying degrees of correlations with Dkk-3, CAF22 and selected micro RNAs (miRs) in respiratory diseases. Taken together, our data show that plasma levels of Dkk-3, CAF22 and selected miRs can be useful tools to assess accelerated sarcopenia phenotype in the elderly with respiratory diseases.
  • ||||||||||  Review, Journal:  Nutrition and microRNAs: Novel Insights to Fight Sarcopenia. (Pubmed Central) -  Oct 8, 2020   
    Besides, we explored the role of nutrition as a possible way to counteract the loss of muscle mass and function associated with ageing, with special attention paid to nutrient-dependent miRNAs regulation. This review will provide important information to better understand sarcopenia and, thus, to facilitate research and therapeutic strategies to counteract the pathophysiological effect of ageing.
  • ||||||||||  [VIRTUAL] The impact of body composition on long‐term outcomes in patients with colorectal cancer () -  Oct 8, 2020 - Abstract #ESCP2020ESCP_225;    
    This review will provide important information to better understand sarcopenia and, thus, to facilitate research and therapeutic strategies to counteract the pathophysiological effect of ageing. Visceral obesity does not seem to affect long‐term outcomes of patients with CRC, while sarcopenia presents a negative prognostic impact on both OS and CRS.
  • ||||||||||  everolimus / Generic mfg.
    [VIRTUAL] Prognostic value of sarcopenia in metastatic renal cell carcinoma patients: A systematic review (On-Demand e-Poster Display) -  Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1252;    
    However, other 2 studies found that there were no significant differences in chemotherapy toxicity between sarcopenic and non-sarcopenic patients treated with tyrosine kinase inhibitor and everolimus...Legal entity responsible for the study: The authors. Funding: Has not received any funding.
  • ||||||||||  everolimus / Generic mfg.
    [VIRTUAL] Prognostic value of sarcopenia in metastatic renal cell carcinoma patients: A systematic review (On-Demand e-Poster Display) -  Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_887;    
    However, other 2 studies found that there were no significant differences in chemotherapy toxicity between sarcopenic and non-sarcopenic patients treated with tyrosine kinase inhibitor and everolimus...There were 5 studies with good quality, 4 studies with moderate quality, and 1 study with poor quality. Further investigation is needed with better methods and outcome that focuses on chemotherapy toxicity and quality of life.
  • ||||||||||  everolimus / Generic mfg.
    [VIRTUAL] Prognostic value of sarcopenia in metastatic renal cell carcinoma patients: A systematic review (On-Demand e-Poster Display) -  Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_518;    
    However, other 2 studies found that there were no significant differences in chemotherapy toxicity between sarcopenic and non-sarcopenic patients treated with tyrosine kinase inhibitor and everolimus...There were 5 studies with good quality, 4 studies with moderate quality, and 1 study with poor quality. Further investigation is needed with better methods and outcome that focuses on chemotherapy toxicity and quality of life.
  • ||||||||||  prednisone / Generic mfg.
    [VIRTUAL] Frailty and Health-Related Quality of Life in Patients with Polymyalgia Rheumatica () -  Oct 8, 2020 - Abstract #ACRARHP2020ACR_ARHP_1013;    
    Frailty was associated with worse physical function and increased fatigue, pain behavior and pain interference, differences that were clinically meaningful and statistically significant. Study limitations include the relatively small, homogenous sample size and missing data regarding sarcopenia.
  • ||||||||||  Review, Journal:  Hepatic Encephalopathy and Nutrition Influences: A Narrative Review. (Pubmed Central) -  Oct 7, 2020   
    This debilitating condition is associated with increased morbidity and mortality and imposes a significant burden on the caregivers and healthcare system. After providing an overview of HE epidemiology and pathophysiology, this review focuses on the interaction of HE and frailty, nutrition requirements and recommendations in cirrhotic patients with HE, and current dietary and pharmacologic options for HE treatment.
  • ||||||||||  Review, Journal:  Mitochondrial Dysfunction in Kidney Disease and Uremic Sarcopenia. (Pubmed Central) -  Oct 7, 2020   
    This review provides an overview of the mitochondrial change in the kidney and skeletal muscle, which is often complicated with sarcopenia and chronic kidney disease (CKD). Furthermore, the pharmacological effects of therapeutics for CKD on mitochondria are explored.